In the latest trading session, 83.23 million Black Diamond Therapeutics Inc (NASDAQ:BDTX) shares changed hands as the company’s beta touched 2.79. With the company’s most recent per share price at $2.23 changing hands around $0.55 or 33.04% at last look, the market valuation stands at $126.64M. BDTX’s current price is a discount, trading about -243.5% off its 52-week high of $7.66. The share price had its 52-week low at $1.59, which suggests the last value was 28.7% up since then. When we look at Black Diamond Therapeutics Inc’s average trading volume, we note the 10-day average is 0.39 million shares, with the 3-month average coming to 768.64K.
Analysts gave the Black Diamond Therapeutics Inc (BDTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.14. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BDTX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Black Diamond Therapeutics Inc’s EPS for the current quarter is expected to be -0.27.
Black Diamond Therapeutics Inc (NASDAQ:BDTX) trade information
Instantly BDTX is in green as seen in intraday trades today. With action 24.86%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 4.44%, with the 5-day performance at 24.86% in the green. However, in the 30-day time frame, Black Diamond Therapeutics Inc (NASDAQ:BDTX) is -1.97% down. Looking at the short shares, we see there were 7.41 million shares sold at short interest cover period of 13.94 days.
The consensus price target for the stock as assigned by Wall Street analysts is 14, meaning bulls need an upside of 84.07% from its recent market value. According to analyst projections, BDTX’s forecast low is 11 with 20 as the target high. To hit the forecast high, the stock’s price needs a -796.86% plunge from its current level, while the stock would need to soar -393.27% for it to hit the projected low.
Black Diamond Therapeutics Inc (BDTX) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -5.22%. The 2025 estimates are for Black Diamond Therapeutics Inc earnings to increase by 21.15%, but the outlook for the next 5-year period is at -2.97% per year.
Black Diamond Therapeutics Inc (NASDAQ:BDTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.70% of Black Diamond Therapeutics Inc shares while 97.51% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 100.22%. There are 97.51% institutions holding the Black Diamond Therapeutics Inc stock share, with T. ROWE PRICE INVESTMENT MANAGEMENT, INC. the top institutional holder. As of 2024-06-30, the company held 20.5751% of the shares, roughly 10.66 million BDTX shares worth $49.67 million.
BELLEVUE GROUP AG holds the second largest percentage of outstanding shares, with 16.4409% or 8.52 million shares worth $39.69 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Price (T.Rowe) Small-Cap Value Fund and Price (T.Rowe) Small Cap Stock Fund. With 2.42 shares estimated at $5.41 million under it, the former controlled 4.28% of total outstanding shares. On the other hand, Price (T.Rowe) Small Cap Stock Fund held about 4.19% of the shares, roughly 2.37 shares worth around $5.29 million.
